Inozyme Pharma Inc. (INZY): Price and Financial Metrics
INZY Price/Volume Stats
| Current price | $4.33 | 52-week high | $7.80 |
| Prev. close | $4.40 | 52-week low | $2.69 |
| Day low | $4.18 | Volume | 627,400 |
| Day high | $4.49 | Avg. volume | 618,575 |
| 50-day MA | $5.83 | Dividend yield | N/A |
| 200-day MA | $4.74 | Market Cap | 267.47M |
INZY Stock Price Chart Interactive Chart >
Inozyme Pharma Inc. (INZY) Company Bio
Inozyme Pharma engages in the research and development of pharmaceutical products. It specializes in developing new medicines for the treatment of abnormal mineralization and ABCC6 deficiency. The company was founded by Axel Bolte, Joseph P. Schlessinger and Demetrios T. Braddock in September 2015 and is headquartered in Boston, MA.
Latest INZY News From Around the Web
Below are the latest news stories about INOZYME PHARMA INC that investors may wish to consider to help them evaluate INZY as an investment opportunity.
Institutional investors own a significant stake of 45% in Inozyme Pharma, Inc. (NASDAQ:INZY)Key Insights Given the large stake in the stock by institutions, Inozyme Pharma's stock price might be vulnerable to... |
Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)BOSTON, Dec. 05, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“Company” or “Inozyme”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced that it granted stock options to a new employee to purchase shares of the Company’s common stock, pursuant to the Company’s 2023 Inducement Stock Incentive Plan, as inducement material to the new employee entering into e |
Inozyme Pharma to Participate in Upcoming Investor ConferencesBOSTON, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“Inozyme” or the “Company”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced that Douglas A. Treco, Ph.D., the Company’s chief executive officer and chairman of the board, will participate at the following investor conferences: The Jefferies London Healthcare Conference. The presentation will |
Inozyme Pharma Reports Third Quarter 2023 Financial Results and Provides Business Highlights– Patient recruitment underway in ENERGY-3 Pivotal Trial of INZ-701 in pediatric patients with ENPP1 Deficiency; topline data expected mid-2025 – – Topline data readouts from ongoing Phase 1/2 trials of INZ-701 in adults with ABCC6 Deficiency and ENPP1 Deficiency expected in first quarter of 2024 – – Cash, cash equivalents, and short-term investments as of September 30, 2023 expected to fund operations into the fourth quarter of 2025 – BOSTON, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, In |
Inozyme Pharma Announces Presentation at the American Society of Nephrology (ASN) Kidney Week 2023BOSTON, Oct. 26, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“Inozyme” or the “Company”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced an oral presentation at the American Society of Nephrology (ASN) Kidney Week 2023, which is being held November 2-5, 2023 in Philadelphia, PA. Details of the presentation are as follows: Title: Role of Plasma Inorgan |
INZY Price Returns
| 1-mo | -41.41% |
| 3-mo | -8.07% |
| 6-mo | 59.78% |
| 1-year | -18.76% |
| 3-year | -77.00% |
| 5-year | N/A |
| YTD | 1.64% |
| 2023 | 305.71% |
| 2022 | -84.60% |
| 2021 | -66.96% |
| 2020 | N/A |
| 2019 | N/A |
Loading social stream, please wait...